Scholar Rock Holding Corporation

NASDAQ:SRRK

Biotechnology

Healthcare
$48.00 +1.03%

+$0.49 today

Market cap
$5.86B
Beta
0.69
P/E (TTM)
-14.8
EPS (TTM)
-$3.21
52W Low $27.07High $52.19

Volume 2.77M

Average 1.46M

SRRK Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Scholar Rock Holding CorporationNASDAQ: SRRK

Revenue · Q3 FY2026 · quarter ended Sep 2026

Revenue remains negative

Q3 FY2026 revenue was $570K, compared with $0 a year earlier. Trailing-twelve-month revenue was $570K.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly revenue holds near $570K or moves back toward the trailing-twelve-month quarterly average of $142.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$570K— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2026
$570K— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How SRRK compares with its peers on the latest reported figures

  • SRRK's LTM Sep 2026 revenue of $570K is the 8th highest of the 11 companies compared; the peer median is $94.06M.
SRRK Competitors Peer median
Revenue for SRRK and competitors
Company Period LTM YoY 3-year CAGR
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$2.18B -2.2%+33.1%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$1.01B -42.8%+35.3%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$959.76M -0.7%+17.1%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$713.07M +202.4%+86.3%
BEAMBeam Therapeutics Inc.LTM Jun 2026$156.04M +158.9%+31.9%
STOKStoke Therapeutics, Inc.LTM Mar 2026$32.08M -83.2%+145.9%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$20M -88.1%—
SRRKScholar Rock Holding CorporationLTM Sep 2026$570K ——
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$0 ——
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$0 -100.0%-7.4%
DYNDyne Therapeutics, Inc.LTM Jun 2026$0 ——
Peer median (excluding SRRK) $94.06M-22.5%+33.1%

Competitors are the stored peer set for SRRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.82M33.19M000
Cost of Revenue108.47M123.04M2.84M1.94M208.44M
Gross Profit(89.65M)(89.85M)(2.84M)(1.94M)(208.44M)
Gross Margin-476.5%-270.7%———
Research & Development108.47M124.44M119.06M182.61M208.44M
Selling, General & Admin40.27M42.62M49.4M67.5M176.21M
Operating Expenses40.27M44.52M168.45M250.12M176.21M
Depreciation & Amortization2.63M2.99M2.84M1.94M1.66M
EBITDA(129.17M)(129.48M)(162.95M)(237.52M)(369.39M)
EBITDA Margin-686.5%-390.1%———
Operating Income(129.92M)(134.37M)(171.3M)(252.05M)(384.65M)
Operating Margin-690.5%-404.8%———
Interest Income00012.68M13.9M
Interest Expense0006.84M6.89M
Other Income / Expenses(1.88M)(132K)5.51M5.76M6.71M
Income Before Tax(131.8M)(134.5M)(165.79M)(246.29M)(377.94M)
Pre-Tax Margin-700.5%-405.2%———
Income Tax Expense00000
Net Income(131.8M)(134.5M)(165.79M)(246.29M)(377.94M)
Net Margin-700.5%-405.2%———
EPS (Basic)(3.59)(2.21)(1.99)(2.47)(3.29)
EPS (Diluted)(3.59)(2.21)(1.99)(2.47)(3.29)
Weighted Avg Shares36.71M59.61M75.98M99.84M114.7M
Weighted Avg Shares (Diluted)36.71M59.61M75.98M99.84M114.7M

Scholar Rock Holding Corporation

NASDAQ:SRRK

Intrinsic Alpha fair value

Locked

Current Price

$48.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.